Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Summary

The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 microgram tiotropium bromide solution for inhalation, delivered by the Respimat® inhaler, once daily for four weeks in patients with chronic obstructive pulmonary disease (COPD).

Timeline

Start

2008-07

Primary completion

2009-02

Completion

—

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Olo 2 µg + Tio 5 µg vs Olo 5 µg + Tio5 µg; p = 0.8937; NCT00720499 ↗

Drugs

Indications